INTEG-BNasdaq StockholmMedical DevicesIFRS · SEK

Integrum

Integrum is a Swedish medical technology company focused on osseointegration systems that connect prosthetic limbs directly to the skeleton. Its core offering is the OPRA Implant System, supported by surgical procedures, implant components, and related devices used through a network of specialist clinics and Centers of Excellence, with the US as its main market and additional activity in Europe and other international markets.

Business

Share of revenue
OPRA Implant System55 %

Implant-based osseointegration system used to attach prosthetic limbs directly to bone.

Surgical procedures25 %

First- and second-stage procedures performed by specialist surgeons to implant and complete the system.

Axor II and related components15 %

Safety coupling and accessory components used with the implant system and prosthetics.

Clinical support and training5 %

Education, onboarding, and support services for clinics and partner hospitals.

Customers

Integrum sells primarily to specialist hospitals, orthopedic surgeons, and rehabilitation-focused clinics that treat amputees and complex prosthetic patients. The company also serves patients indirectly through its clinical partners, since the treatment pathway depends on surgeon adoption, center-of-excellence workflows, and follow-up care. Demand is driven by providers seeking advanced prosthetic solutions and by patients who need improved mobility and long-term function.

Specialist hospitals

Buy the implant system and procedures for advanced amputee reconstruction and prosthetic attachment.

Orthopedic surgeons

Adopt the OPRA system and perform S1/S2 procedures as part of their surgical practice.

Rehabilitation centers

Support patient evaluation, recovery, and long-term functional follow-up.

Centers of Excellence

Serve as referral and treatment hubs for complex osseointegration cases.

Patients with limb loss

End users of the system, reached through hospitals and specialist clinics.

Strategy

Integrum’s strategy centers on expanding the commercial reach of the OPRA Implant System by concentrating on Centers of Excellence and improving the patient pathway from referral to surgery. The company is also building local market presence in priority regions, strengthening digital tools, and supporting surgeon education to improve conversion and shorten lead times. These actions are intended to make adoption more scalable while preserving the specialist nature of the treatment model.

Concentrate on Centers of ExcellenceShort term

Specialist hubs improve procedure volume, referral quality, and clinical credibility.

Improve digital patient flowShort term

Better intake and follow-up can shorten lead times and improve conversion to surgery.

Expand in priority international marketsMedium term

Broader geographic reach reduces dependence on one market and supports growth.

Strengthen surgeon training and clinical supportMedium term

Adoption depends on surgeon familiarity, procedure quality, and partner confidence.

Geography

Integrum is headquartered in Mölndal, Sweden, and operates through a Swedish parent company with a US subsidiary and international commercial activity. The US is the largest market disclosed in the reports, while Rest of the World includes priority markets such as the DACH region, Ukraine, and Israel. Geography matters because the business depends on local surgical adoption, clinic partnerships, reimbursement conditions, and the pace of market access in each country.

Risks

Integrum’s business depends on surgeon adoption, reimbursement, and the pace at which clinics move from interest to active procedures, which can make revenue lumpy and market-specific. The company also faces operational and regulatory risks tied to product quality, certifications, suppliers, foreign exchange, and the execution of a specialized medical procedure model. Because a large share of activity is concentrated in the US and in a limited number of centers, changes in clinical demand or market access can have an outsized effect.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Dependence on surgeon and clinic adoption1Geographic concentration in the US2Foreign exchange risk3Regulatory and certification risk4Supplier and product quality risk5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Dependence on surgeon and clinic adoptionImpact: HighLikelihood: Medium

    The system requires specialist training and clinical acceptance before procedures scale.

    Exposure: OPRA Implant System sales and S1/S2 procedure volumes

  2. Geographic concentration in the USImpact: HighLikelihood: Medium

    A large share of revenue comes from one market, making results sensitive to local demand and reimbursement.

    Exposure: US market revenue and procedure activity

  3. Foreign exchange riskImpact: MediumLikelihood: High

    The company reports in SEK but earns revenue in multiple currencies, creating translation and transaction effects.

    Exposure: US and international operations

  4. Regulatory and certification riskImpact: MediumLikelihood: Medium

    Medical device commercialization depends on permits, certifications, and compliance.

    Exposure: Product approvals and market access

  5. Supplier and product quality riskImpact: MediumLikelihood: Medium

    Specialized implants and components must meet strict quality standards to avoid disruption or recalls.

    Exposure: Implant system components and surgical kits

Accounting

Judgemental items
Capitalized development expenditures

Management must judge whether product development qualifies for capitalization and future recovery.

Impact: Affects intangible assets, operating expenses, and impairment risk

Revenue timing across staged procedures

S1, S2, and component sales occur at different points in the treatment cycle.

Impact: Can create quarter-to-quarter volatility in reported sales

IFRS 16 leases

Office and facility leases are recognized on the balance sheet and affect expense presentation.

Impact: Changes lease liabilities, depreciation, and interest expense

Foreign exchange translation

Internal loans and foreign operations create translation effects under IAS 21.

Impact: Can move equity and other comprehensive income

Impairment testing

Capitalized development assets are tested for recoverability using value-in-use estimates.

Impact: Potential write-downs if expected cash flows weaken

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026